HEAD-Study Optimizing the Treatment of Children With BECTS — HEAD

Epilepsy, Rolandic Clinical Trial

Official title:
HEAD-TO-HEAD Evaluation of the Antiepileptic Drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German Multi-Centre, Doubleblind Controlled Trial in Children With Benign Epilepsy With Centro-Temporal Spikes

Status Terminated

Clinical Trial Summary

The investigators hypothesize that Levetiracetam is as effective as Sulthiame in the treatment of children with BECTS. Patients entering the HEAD-Studie are either treated with Leveitracetam or Sulthiame over a 6 months period. Patients are equally randomised to one of the two treatment regimens. Administration of medication as blinded capsules.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00471744
Study type	Interventional
Source	Ludwig-Maximilians - University of Munich
Contact
Status	Terminated
Phase	Phase 3
Start date	June 2006
Completion date	July 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03465566` - Emotion Recognition in Benign Epilepsy of Childhood With Centro-Temporal Spikes (BECTS)
Completed	`NCT04954729` - Association of Processing Speed Dysfunction and Brain Functional Abnormality in ECTS
Completed	`NCT00216567` - Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy	Phase 4